In this study, age, sex, recurrence, metastasis, death rate, and histologic patterns were in agreement with those of previous reports on canine mast cell tumors. Histologic grading, mitotic index, chromosome nucleolar organizer regions stained with silver (AgNORs), and anti-proliferating cell nuclear antigen (PCNA) were evaluated as indicators of prognosis. Histologic grading, AgNORs estimated in 100 cells, and PCNAlabeled fraction estimated in five high power fields (HPFs) were significantly different between recurring and nonrecurring tumors. Those prognostic factors were also significantly different between tumors that metastasized and those that did not. The survival time was lower in dogs with mast cell tumors with histologic grade 3 (Patnaik's), AgNOR counts higher than 2.25, and PCNA count in five HPFs higher than 261. The significance of these factors as markers for prognosis determined by logistic regression analysis differed with the time period considered. By combining the three most significant prognostic factors in a prognostic index, three models were obtained to determine the probability of nonrecurrence at 3, 6, and 9 months after surgery. The models were accurate in the prediction of the outcome of up to 80% of mast cell tumors. The use of these models provides a less subjective means of prognosticating mast cell tumors than the use of any one component alone.
Mast cell tumors are among the most common skin neoplasms in d o g~.~J~,~~,~~ They tend to occur in middle-aged to elderly dog^,'^,'^,^^ with a predominance in Boxers, terriers, and Labrador Mast cell tumors in dogs are potentially malignant.28,32 Data compiled from 2 1 reports showed that metastasis to regional lymph nodes was present in 76% of affected dogs.15 Recurrence or tumor-related death has been estimated to be 3.5O/0,'~ 1 7 O / 0 ,~~ 38O/0,~ and 46O/0.~~ Most recurrences occurred within 4 months after surgery,24 but longer intervals have been reported. I4 Six months was indicated as the average survival time in dogs with recurrent mast cell tumors.2
The gradation of malignancy of mast cell tumors has long been recognized.6 R e c~r r e n c e ,~.~~~~~ survival time,2,28 and rnetasta~is'~ have been associated with the degree of cellular differentiation. Two grading systems correlate the histologic patterns of mast cell tumors with prognosis.2,28 The differences between these grading systems result from subjectivity in the evaluation of the histologic features.I9 Grading systems for mast cell tumors can predict the probability of survival but are of less value in borderline cases.2.28
Histologic criteria alone may be of limited value in predicting the outcome of mast cell tumors.26 Chromosome nucleolar organizer regions stained with silver (AgNORs) correlated with survival in dogs with mast cell turn or^,^ but this method was more reliable in extreme cases. Ploidy of canine mast cell tumors determined by flow cytometry had little prognostic significance.
The prognosis of mast cell tumors was associated with the growth fraction estimated by the frequency of m i t~s e s .~~~. '~,~'~~~ However, even highly malignant mast cell tumors usually have a low mitotic count, making it a relatively insensitive measure of tumor b e h a~i o r .~ Therefore, alternative methods to estimate growth fraction must be considered to predict the outcome of mast cell tumors.
Antibodies against proliferate cell nuclear antigen (PCNA), which is associated with the growth fraction, correlated with prognosis in several types of human turn or^.",'^,^^,^^,^^ PCNA is a 36-kd acidic nonhistone protein required for DNA synthesis through its relation with polymerase delta.4
The monoclonal antibody 19A2 is an IgM that recognizes PCNA.25 The cell fraction labeled by 19A2 has a close correlation with cells in S-phase, determined by flow cytometry using microwave-treated tissues in a high-metal salt
The evaluation of markers for cell proliferation as indicators of prognosis in canine mast cell tumors has been suggested.'
The purpose of this study was to compare histologic grading, mitotic index, AgNOR counts, and PCNA as markers for prognosis. A prognostic index for canine mast cell tumors is proposed based on the most significant indicators of prognosis.
Materials and Methods

Tumors
One hundred twenty-two tumors consecutively diagnosed as mast cell tumors in dogs were used in this study. Tumors were obtained through the biopsy service of the Department of Veterinary Diagnostic Investigations, Kansas State University, during 1990.
The biologic behavior of the tumors was investigated by means of a questionnaire sent to each referring veterinarian. The questionnaire requested information on breed, sex, and age of the dog, interval in weeks between first observation and removal of the tumor, size and tumor location, additional treatment after surgery, date of recurrence and/or metastasis, date of last follow-up visit, and date and cause of death.
Histologic grading and mitotic counting
One hundred twelve tumors were available for histologic examination. Two 5-pm sections were obtained from each tumor. One section was stained with hematoxylin and eosin (HE), and the other was stained with Giemsa. Each tumor was graded by one of us (J. P. C. Simoes) according to the criteria proposed by Patnaik et These criteria included uniformity in cell size and shape, size of the cytoplasmic granules, nuclear shape and staining, number of nucleoli, incidence of mitotic figures, necrosis, and stroma. Mitotic figures were counted in anti-PCNA-stained sections and expressed as a percentage in a total of 1,000 cells present in the same tumor areas where PCNA indexes were estimated.
AgNOR stain
Tissues were stained for AgNORs according to a previously described meth0d.3~ The 5-pm sections were deparaffinized in xylene and passed through 100% ethanol. Sections were stained in a solution of 2% gelatin and 1% formic acid in ultrapure water mixed 1 : 2 with 50% silver nitrate. Tissues were incubated for 20 minutes at room temperature and protected from light then washed in ultrapure water and placed in 5% thiosulfate solution for 2 x 5 minutes. Tissues were washed again with distilled water, counterstained with light green, dehydrated, cleared in xylene, and mounted in synthetic medium.
PCNA labeling
The 5-pm sections were placed on glass slides treated with Vectabond (Vector Laboratories, Burlingame, CA) and dried overnight at room temperature. The tissues were deparaffinized in xylene, rehydrated in loo%, 95%, and 70% alcohol (2 x 4 minutes), and placed in distilled water for 10 minutes. Sections were treated with antigen retrieval solution (Biogenex Laboratory, San Ramon, CA) diluted 1 : 4 in distilled water in a Coplin jar and subjected to microwaves at medium high power (maximum output = 700 W) for 2 x 5 minutes.
Slides were cooled to room temperature for 15 minutes and washed once in distilled water.
Endogenous peroxidase was blocked with 3% H20, for 10 minutes, then the slides were washed briefly in phosphatebuffered saline (PBS). Normal mouse serum, as a protein blocking agent, was applied for 20 minutes. The tissues then were incubated with the monoclonal antibody 19A2 (Biogenex Laboratory) diluted 1 : 200 in PBS/0.001% Tween 20 overnight in a humidity chamber.
The second stage antibody, biotinylated goat IgG antimouse IgM-p-chain specific (Vector Laboratories) was applied at a concentration of 1 : 400 in PBS for 1 hour. The tissues were then incubated for 45 minutes, with avidinbiotin complex (Vectastain Elite, Vector Laboratories) diluted in a high-salt solution (0.125 M Tris-buffered saline containing 0.374 M NaC1, pH 7.4) to reduce avidin binding to the mast cell granules.I6 Sections then were incubated with amino-ethylcarbazole (AEC, Vzctor Laboratories), and color development was monitored under the microscope.
Incubation times and the concentrations of the antibodies were chosen after varying these factors for 15 tumors.
The tissues were counterstained with Mayer's hematoxylin for 20 seconds and washed in tap water. Crystal Mount (Biomeda, Foster City, CA) was applied, and the sections were dried at 60 C for 15 minutes. Each step was followed by a 2
x 5 minute wash in PBS.
Selected sections, in which the primary antibody was replaced by goat serum, were used as negative controls. Each slide acted as an internal positive control, because cells such as those in the basal layer of the epidermis are normally dividing.
Scoring of 19A2 and PCNA
AgNORs in 100 and 200 cells (AgNOR 100 and AgNOR 200, respectively) selected at random were counted under oil (1,000 x ) using an American Optical microscope, and 10-20 cells were considered per field. All AgNOR dots, either associated with the nucleolus or scattered in the n u c l e~s ,~ were counted.
The PCNA index was calculated as the number of positive tumor nuclei based on counting 500 and 1,000 cells (PCNA 500 and PCNA 1,000, respectively) under oil (1,000~). A semiquantitative estimation of the proliferative fraction was obtained by counting the number of positive nuclei in five high power fields (HPFs, 400 x). All identifiable red nuclear staining was regarded as and only the most immunopositive areas of the tumors were considered. 17.39.42
Statistical analysis
To identify the variables that best predicted the outcome in dogs with mast cell tumors, logistic regression with a stepwise backward elimination approach was used. The procedure, "Proc Probit" with a logistic distribution option, was used in a SAS statistical package for the personal computer (PC). The variables of less significance were excluded from the model using a = 0.1. In this model, the probability for the dogs to remain disease free after surgery was estimated based on recurrence at 3, 6, and 9 months.
Differences between mitotic index, AgNOR counts, and PCNA counts in recurring and nonrecurring tumors and tumors that metastasized or did not metastasize were determined using Student's t-test. Linear regression analysis was used to correlate mitotic index, AgNOR counts, and PCNA counts, and significance was determined by a t-test. For each variable with prognostic value, subgroups were created based on each median value. Accordingly, for each subgroup, the survival of dogs with mast cell tumors from the time of surgery to date of death or last follow-up was plotted by the Kaplan-Meier method for censored variables using "Proc Lifetest" in the SAS statistical package for the PC. Survival for each subgroup was compared by the logrank and Wilcoxon methods.
The level of significance was set at a = 0.05 unless otherwise indicated.
Results
Thirty-one dog breeds were recorded. Mixed breeds (15, 12.5%), Boxers (13, 10.8%), Labrador Retrievers (1 3, 10.8%), and terriers (eight, 6.7%) were most common. Mast cell tumors were more frequent on the thorax, hind legs, and abdomen (Table 1) . Distribution by location was 57.9% on the skin of the abdomen, hind legs, and genital area; 28.9% on the forelegs and thorax; and 13.2% on the head and neck. Four dogs (3.3%) had multiple tumors. The tumors were 0.5-20 c m in size, with a median of 2.5 cm and a mean (+ SD) of 3.3 -t 3.0 cm.
Information regarding sex and age of dog, tumor recurrence, metastasis, and mortality are presented in Table 2 . There was no significant difference between the number of males (46, 40%) and females (70,6O%). The mean age at the time of surgery was 8.0 f 2.9 years; ages ranged from 1 month to 17 years, with no difference between males or females.
Follow-up information was available on 90 tumors (Table 2) . Information on the interval between the time the tumor was recognized and surgery and on the interval between recognition of recurrence and last contact with the veterinarian seldom were provided in the questionnaire. Therefore, they were not considered. The median and mean (+ SD) times from surgery to death or last follow-up visit were 714 and 602.7 -+ 357.93 days, respectively. Tumors recurred in 30 dogs (33.3%). Eighteen dogs (20.0%) had metastases at the time of death. Twenty-four dogs (26.7%) died or were euthanatized as a consequence of the tumor, and 14 dogs (1 5.2%) died from unrelated causes. The median and the mean (+ SD) interval between surgery and Recurrence or absence of recurrence was not significantly different between males and females. Recurrence among breeds was not evaluated because of low representation of most breeds. The mean (k SD) ages at surgery were 7.3 * 0.4 years for dogs without recurring tumors and 9.1 It_ 0.5 years for those in which tumors recurred. These differences were significant. The mean size of the primary tumor did not influence recurrence or nonrecurrence of tumors.
Histopathology
Data on survival and histologic grading were available for 87 tumors. Thirty-three tumors (38%) were well differentiated or Patnaik grade I, 35 (40%) were of intermediate differentiation or grade 11, and 19 (22%) were poorly differentiated or grade 111. Nine percent of dogs with grade I tumors, 29% with grade 11, and 58% with grade 111 died or were euthanatized as a result of incurable tumor (Table 3) . Recurrence and death rate were significantly lower in dogs with grade I than in dogs with grade I11 tumors. The histologic characteristics of the mast cell tumors with distribution by grade and by recurrence/nonrecurrence are summarized in Table 4 .
The histologic features on HE-stained sections included the following. An incomplete fibrous capsule surrounded 2.6% of the tumors, with neoplastic cells infiltrating the lower dermis and subcutis. A pattern of distribution in which the cells were scattered diffusely was most common (39.1%); uniform sheets of cells were present in 31.0% and a mixed pattern in 20.7% of the tumors. Cords and nests of cells were present in 4.6% and 3.4% of the tumors. respectively. The stroma was fine in 65.5%, moderately abundant in 26.4%, and in large collagen bundles in 8.0% of the tumors. Grade I and I1 tumors were significantly different from grade 111 tumors. Cells were uniform in size in 48.3% of the tumors, anisocytosis was present in 26.4% of the tumors, and anisocytosis and giant cells were present in 25.3% of the tumors. Cells were uniform in shape in 52.9% of the tumors. Cell size and cell shape varied significantly between grade I and I11
tumors. Cytoplasm was abundant in 83.9% of the tumors. The cytoplasmic granules were largest in grade I tumors dustlike in grade I11 tumors. Cytoplasmic vacuoles were present in 9.2% of the tumors, with no difference between grades.
The nuclei were uniform in size in 4 1.1 O/ o and round to oval in 60.9% of the tumors. The nuclei stained dark with clumped chromatin in 70.1% of the tumors. Differences in nuclear size, shape, and staining characteristics were significant between grade I and 111 tumors. The nucleoli were not visible in 69.0% of the tumors, and 3.4% had more than one nucleolus. The average numbers of mitotic figures per 1,000 cells were 4.2, 8.3, and 11.0 for grade I, 11, and 111 tumors, respectively. The differences were statistically significant.
Vascular changes such as hyalinization, thickening, and infiltration of cells into vascular walls were present in 75.9% of the tumors. Differences between grade I and grade I1 tumors were significant. Eosinophils were not seen in 8.0% of the tumors, and they were <50/ HPF in 40.2% and > 5O/HPF in 5 1.7% of the tumors. Their distribution was predominantly diffuse. Most tumors were infiltrated by other inflammatory cells, mainly lymphocytes and plasma cells. Foci of necrosis were present in 13.3% of the tumors.
Several histologic features were significantly different between primary tumors that recurred and those that did not (Table 4) . Cell size and shape were more uniform in tumors that did not recur. The mean (k SD) number of mitotic figures per 1,000 cells was 9.4 k 0.9 in recurring and 5.8 k 0.6 in nonrecurring tumors. The difference was significant. However, the mean mitotic index was not significantly different in tumors that metastasized or did not metastasize. The infiltrative characteristics and distribution patterns of neoplastic cells were not significantly different in recumng and nonrecumng tumors. Changes in blood vessels and presence and distribution of eosinophils and other inflammatory cells were not significantly different. Increases in the amount of cytoplasm, granule size, and nuclear size and lack of a visible nucleolus were predominant in nonrecurring tumors, but differences were not significant.
Mitotic figures were recognized readily in sections stained with anti-PCNA and counterstained with Mayer's hematoxylin. Mitotic index estimated per 1,000 cells correlated poorly with AgNOR 100 ( r = 0.2), AgNOR 200 (Y = 0.3), PCNA 500 (Y = 0.3), PCNA 1,000 ( r = 0.4), and PCNA estimated in five HPFs ( r = 0.5).
AgNORs
In most sections, AgNORs were easy to recognize (Fig. 1 ). They were identified as dark brown to black dots associated with the nucleoli.
AgNOR 100 and AgNOR 200 counts were significantly different between recurring and nonrecurring tumors. The AgNOR 100 and AgNOR 200 counts had a very high correlation ( r = 0.96), indicating a low intraobserver variation. The mean (k SD) AgNOR 100 counts were 2.2 -t 0.1 in nonrecurring and 2.9 * 0.2 in recurring tumors. The AgNOR 200 counts were 2.2 k 0.2 in nonrecurring and 2.9 * 0.5 in recurring tumors.
The differences in AgNOR 100 and AgNOR 200 counts were significantly different between tumors that metastasized and those that did not. The mean (f SD) AgNOR 100 counts were 2.3 k 0.1 in nonmetastasizing and 2.8 k 0.2 in tumors that metastasized. The AgNOR 200 counts were 2.2 k 0.2 and 2.9 k 0.4 in tumors that did not metastasize and did metastasize, respectively.
PCNA
The nuclei of mast cells positive for PCNA stained orange to red, usually with a granular pattern (Fig. 2) . Distribution of positive cells varied greatly within and among tumors. Pretreatment with the antigen retrieval solution was essential to increase the number of tumors positive for PCNA. Other cells were also positive. In the epidermis, staining was irregularly confined to the cells in the basal layer. Some cells of the follicular epithelium and occasionally sebaceous and sweat glands also were positive. Occasionally, cells in mitoses did not stain.
The PCNA 500 and PCNA 1,000 estimates had a high linear correlation ( r = 0.94), indicating a low intraobserver variability. The PCNA estimated in five HPFs correlated with PCNA 500 estimates ( r = 0.47) and PCNA 1,000 estimates ( r = 0.45). PCNA-positive cells were significantly different in recurrent and nonrecurrent tumors, regardless of whether five HPFs, 500 cells, or 1,000 cells were counted. Mean (k SD) PCNApositive cells in tumors that did not recur were 105.1 ? 7.7 (21.0%) in PCNA 500 counts, 204.8 ? 15.1 (20.5%) in PCNA 1,000 counts, and 393.1 k 82.3 in five HPFs. In tumors that recurred, the mean (k SD) number of PCNA-positive cells were 167.4 -t 10.9 (33.4%) in PCNA 500 counts, 339.7 k 21.2 (34.0%) in PCNA 1,000 counts, and 875.8 k 115.4 in five HPFs.
Regardless of the method of estimation, PCNA counts were significantly higher in tumors that metastasized than in those that did not. The mean (k SD) PCNA counts in tumors that did not metastasize were 114.1 k 7.3 (22.8%) in PCNA 500 counts, 225.2 k 14.5 (22.5%) in PCNA 1,000 counts, and 451.2 k 76.6 Table 5 . Canine mast cell tumors in which the actual outcome coincided with the prognostic indexes for 3, 6, and 9 months postsurgery, at different P values (n = 88; 28 tumors recurred). AgNOR 100 and AgNOR 200 counts had low linear correlation (Y = 0.2) with PCNA 500 counts, PCNA 1,000 counts, and number of PCNA-positive cells per five HPFs.
Prognosis
The mean age at the time of surgery, mitotic index, AgNOR counts (in 100 and 200 cells), and PCNA estimates (in 500 cells, 1,000 cells, and five HPFs) were different between the group in which tumors recurred and the group that remained tumor free. Therefore, these variables, plus the histologic classification, were used in the backward elimination logistic regression analysis to determine the best predictors for nonrecurrence at 3, 6, and 9 months postsurgery.
The regression models determined to be the best predictors of nonrecurrence included histologic classification, the AgNOR 100, and PCNA-labeled fraction estimated by counting five HPFs (PCNA-5HPFs).
AgNOR 100 was the best predictor for the 3-month nonrecurrence period (P = 0.041), followed by PCNA-5HPFs ( P = 0.062) and histologic classification (P = 0.075). PCNA-5HPFs was the best predictor for the 6-month nonrecurrence period (P = 0.0 lo), followed by histologic classification (P = 0.024) and AgNOR 100 (P = 0.1 1). Histologic classification was the best predictor for the 9-month nonrecurrence period (P = 0.0028), followed by PCNA-5HPFs (P = 0.033) and AgNOR 100 (P = 0.080).
The models were applied to the data in this study, and nonrecurrence was determined for each case, using three levels of significance, P = 0.65, 0.85, and 0.90. The probabilities of nonrecurrence were compared with the information on the actual outcomes in the dogs (Table 5 ). These results suggest that increasing the P value tended to increase the accuracy of identifying recurring tumors but reduced precision in identifying Using the model to predict nonrecurrence during a 9-month period after surgery, with P = 0.85 as the level of significance, the outcome of mast cell tumors was predicted in 23 (82.1%) of recurring tumors, 48 (80.0%) of nonrecurring tumors, and 7 1 (80.6%) of all tumors.
The value of histologic classification, AgNOR 100 counts, and PCNA-5HPFs as predictors of survival time was tested using the Kaplan-Meier method . Overall, 66.7% of the tumors were censored to the right. By choosing a breaking point based on the median for each variable, a significantly higher sur- mors were censored to the right). P = 0.0052 (log-rank test). viva1 time was shown in dogs with an AgNOR 100 lower than 2.25 ( P = 0.0025, log-rank; P = 0.0001, Wilcoxon), a PCNA-5HPFs lower than 26 1 ( P = 0.052, log-rank; P = 0.001 9, Wilcoxon), and a histologic grade of I and I1 ( P = 0.0001, log-rank; P = 0.0001, Wilcoxon).
Discussion
The mean age and the breeds of dogs represented in this study were similar to those in previous reports on canine mast cell t~m~r~.~.~.~~.~~.~~,~~,~~.~~ The predominance of females with mast cell tumors, although not statistically significant, agrees with findings in one report.23 Other researchers have indicated no sex difference in the incidence of these turn or^.'^.^^.^^ The distribution of mast cell tumors and incidence of metastasis were similar to previous finding^.^^.^^ However, one report showed a higher percentage of dogs with metastatic mast cell tumors, possibly reflecting a different duration of the disease.I5
The percentage of dogs that died from mast cell tumors was close to that previously reported.2.28 The average survival time for dogs with mast cell tumors was considerably higher in this study than in others.2 A longer survival time may be related to early surgical intervention.
The percentage of tumors for each of the three histologic grades was similar to the percentages reported by Patnaik et a1.28 ( Table 3 ). The microscopic characteristics of the tumors and their incidence for each histologic grade reflected their degree of differentiation and potential for malignancy. Compared with the study by Patnaik et a1.,28 the percentage of dogs that died from mast cell tumors was lower for grade I1 and 111 and higher for grade I tumors. Therefore, we question the prognostic value of histologic grading used alone. In this study, variation in cell size and shape and mitotic index were the best histologic indicators of recurrence, as noted in other report^.^,^,^^,^^
The results obtained in this study were similar to those of other studies of canine mast cell tumors; therefore, this population may be considered adequate for the evaluation of methods that lead to prognosis and to the formulation of a prognostic index.
The growth fraction estimated as a percentage of mitosis in the tumor cell population31 did not correlate with AgNORs. AgNORs have been reported to be in-dicators of cell proliferation7 and to reflect cell doubling time in tumor cell cultures.* This lack of correlation, also reported by other^,^ suggests that AgNORs and mitotic counts are independent indicators of the growth fraction in canine mast cell tumors.
The mitotic index had a slightly higher correlation with PCNA indexes but not as high as reported for some human t~m o r s .~~,~~ This difference may be explained by the fact that anti-PCNA labels dividing cells22 and cells going through DNA repair.2o Furthermore, because PCNA's half-life is relatively long (about 20 h o~r s ) ,~ it may be present in cells that have already completed mitosis. A high correlation between the growth fraction determined by PCNA labeled with the antigen 19A2 and by flow cytometry (S-phase) was obtained in a much more controlled study, where conditions, such as tissue fixation, were uniform.''
The lack of association between AgNOR counts and anti-PCNA-labeled cells indicates that, contrary to what has been reported by others in human these markers of cell proliferation are independent of each other in canine mast cell tumors.
The results in this study confirm the value of AgNORs as markers for the prognosis of canine mast cell tum o r~.~ AgNORs were also indicators for mast cell tumors with a higher probability of metastasizing. Using the average of 2.25 AgNORs per cell as a breaking point, a lower AgNOR count corresponded significantly to a longer survival period. In the model to determine the probability for nonrecurrence, the predictive value of AgNORs was not increased by counting them in more than 100 cells.
PCNA labeling permitted the distinction between recurring, nonrecurring, and metastasizing tumors. Survival time was significantly longer in cases with a PCNA count in five HPFs of less than 26 1. Therefore, PCNA labeled with 19A2 can be considered a good marker for prognosis of canine mast cell tumors. PCNA labeling was more time consuming than AgNOR counting and showed a larger variability of staining within tumors, even when procedures recommended for antigen retrieval were
The variability in staining patterns suggests that the determination of the cell proliferating fraction by PCNA requires the adoption of a standard for tissue handling, which can be difficult to control in diagnostic cases. However, the irregularity in staining may depend on other factors, because mitotic cells that should have stained were seen in the proximity of stained cells.5
When the regression models were formulated, number of PCNA-positive cells in five HPFs was found to be a better indicator than the percentage of PCNAlabeled cells in 500 or 1,000 cells. The estimation obtained by counting cells per area does not take into account their distribution or size variation and the area of the microscopic field. However, it is faster and includes a larger portion of the tumor cell population.
The value of AgNOR 100, PCNA-SHPFs, and histologic classification in predicting nonrecurrence varied for the three time periods considered. AgNOR 100 was the best predictor for nonrecurrence in the 3-month period and the worst for the 6-and 9-month periods. PCNA-5HPFs was the best predictor in the 6-month period and the second best in the remaining ones. The value of the histologic classification increased from least significant in the 3-month period to most significant in the 9-month period. These findings suggest that AgNOR 100, PCNA-SHPFs, and histologic classification should be combined to get the best prognostic index.
The probabilities for nonrecurrence obtained with the three models resulted in successful prediction of outcome in up to 80% of the tumors ( Table 5 ). Variations in accuracy may be partially justified by the lack of control in tissue handling and, therefore, in immunohistochemical staining. Also, a more uniform follow-up period may give better results. Variation in surgical techniques may also play a role in the lack of consistency between the predicted and the actual outcomes. However, differences in surgical techniques usually are not marked enough to affect outcome,2 and incomplete surgery does not necessarily lead to recurrence.21
A prognostic index must be used with other information, such as tumor growth rate and clinical stage. In spite of its limitations, the application of a prognostic index for mast cell tumors provides a less subjective way to determine the outcome of the disease, without a substantial increase in time and cost. To confirm the validity of this prognostic index, another population should be studied and the data compared.'O In conclusion, this study supports the importance of recognizing mast cell tumors as potentially malignant. The results indicated that nonrecurrence and metastasis of canine mast cell tumors and survival time can be determined by AgNOR counts and anti-PCNA-labeled fraction. Histologic grading also correlated with nonrecurrence and survival time. The value of these prognostic factors varied with the time period considered. This study further indicates that the use of a prognostic index including histologic grading, AgNOR counts, and anti-PCNA-positive fraction may increase the accuracy of prognosis of mast cell tumors in dogs.
